FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
1 min readThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.